Butyrate histone deacetylase inhibitors

BioResearch Open Access

Volumn 1, Issue 4, 2012, Pages 192-198

  Steliou, Kosta ^a,b   Boosalis, Michael S ^b   Perrine, Susan P ^b   Sangerman, José ^b   Faller, Douglas V ^b  

^a PhenoMatriX Inc   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acylcarnitine; Butyrate; Butyrylcarnitine; Carnitine; Histone deacetylase

Indexed keywords

BUTYRIC ACID; HEMOGLOBIN F; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; PIVALOYLOXYMETHYL BUTYRATE; SHORT CHAIN FATTY ACID; TRIBUTYRIN; TRICHOSTATIN A; VORINOSTAT;

APOPTOSIS; ARTICLE; BRAIN ISCHEMIA; CANCER CELL; CANCER INHIBITION; CELL DIFFERENTIATION; CELL DIVISION; CELL TYPE; DNA FRAGMENTATION; DNA SYNTHESIS; ENZYME INHIBITION; FIRST PASS EFFECT; GENE EXPRESSION REGULATION; GYNECOLOGIC CANCER; HUMAN; INSULIN RESISTANCE; LIVER CLEARANCE; MEMORY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OBESITY; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SICKLE CELL ANEMIA; STEM CELL; THALASSEMIA;

EID: 85043492396     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2012.0223     Document Type: Article

References (142)

1. Yoshida M, Kijima M, Akita M, et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990;265:17174-17179.
2. Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: From cells to mice to man. Semin Cancer Biol. 2007; 17:363-369.
3. Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: The next step? Cancer Lett. 2009;280:211-221.
4. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59:111-137.
5. Newkirk TL, Bowersab AA, Williams RM. Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors. Nat Prod Rep. 2009;26:1293-1320.
6. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109:2571-2578.
7. Wang H, Dymock BW. New patented histone deacetylase inhibitors. Expert Opin Ther Patents. 2009;19:1727-1757.
8. Robey RW, Chakraborty AR, Basseville A, et al. Histone deacetylase inhibitors: Emerging mechanisms of resistance. Mol Pharm. 2011;8:2021-2031.
9. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res. 2009;15:3970-3977.
10. Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer. 2009; 45:1129-1136.
11. Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:56-62.
12. Tan J, Cang S, Ma Y, et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3:5.
13. Griffith D, Morgan MP, Marmion CJ. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chem Commun. 2009;45:6735-6737.
14. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov. 2007;6:21-22.
15. Fernández Y, Cueva J, Palomo AG, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev. 2010;36:33-42.
16. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51.
17. Beher D, Wu J, Cumine S, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des. 2009;74:619-624.
18. Wallace DC, Fan W. Energetics, epigenetics, mitochondrial genetics. Mitochondrion. 2010;10:12-31.
19. Dai Y, Faller DV. Transcriptional regulation by class III histone deacetylases (sirtuins). Transl Oncogenomics. 2008;3: 53-65.
20. Smith BC, Hallows WC, Denu JM. Mechanisms and molecular probes of sirtuins. Chem Biol. 2008;15:1002-1013.
21. Bäckdahl L, Bushell A, Beck S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int J Biochem Cell Biol. 2009;41:176-184.
22. Manzo F, Tambaro FP, Mai A, et al. Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Patents. 2009;19:761-774.
23. Munshi A, Shafi G, Aliya N, et al. Histone modifications dictate specific biological readouts. J Genet Genomics. 2009;36: 75-88.
24. Sleiman SF, Basso M, Mahishi L, et al. Putting the 'HAT' back on survival signalling: The promises and challenges of HDAC inhibition in the treatment of neurological conditions. Expert Opin Investig Drugs. 2009;18:573-584.
25. Mellert HS, McMahon SB. Biochemical pathways that regulate acetyltransferase and deacetylase activity in mammalian cells. Trends Biochem Sci. 2009;34:571-578.
26. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325:834-840.
27. Smith KT, Workman JL. Introducing the acetylome. Nat Biotechnol. 2009;27:917-1010.
28. Norvell A, McMahon SB. Rise of the rival. Science. 2010; 327:964-968.
29. Zhao S, Xu W, Jiang W, et al. Regulation of cellular metabolism by protein lysine acetylation. Science. 2010;327:1000-1004.
30. Kouzarides T. Acetylation: A regulatory modification to rival phosphorylation? EMBO J. 2000;19:1176-1179.
31. Chen Y, Sprung R, Tang Y, et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics. 2007;6:812-819.
32. Berndsen CE, Denu JM. Catalysis and substrate selection by histone/protein lysine acetyltransferases. Curr Opin Struct Biol. 2008;18:682-689.
33. ZhangK, ChenY, ZhangZ, et al. Identificationandverification of lysine propionylation and butyrylation in yeast core histones using PTMap software. J Proteome Res. 2009;8:900-906.
34. Adachi M, Monteggia LM. Synergistic interactions between histone deacetylase inhibitors and drugs of abuse. Nat Neuropsychopharmacol. 2009;34:2619-2620.
35. Delage B, Dashwood RH. Dietary manipulation of histone structure and function. Annu Rev Nutr. 2008;28:347-366.
36. McGowan PO, Meaney MJ, Szyf M. Diet and the epigenetic (re)programming of phenotypic differences in behavior. Brain Res. 2008;1237:12-24.
37. Strahl BD, Allis D. The language of covalent histone modifications. Nature. 2000;403:41-45.
38. Perkel JM. Histone code-breakers: The technologies of an epigenetic enigma. Biotechniques. 2010;48:185-191.
39. Yoo CB, Jones PA. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov. 2006;5:37-50.
40. Campos EI, Reinberg D. Histones: Annotating chromatin. Annu Rev Genet. 2009;43:559-599.
41. de Souza M. Primer: Induced pluripotency. Nat Methods. 2010;7:20-21.
42. Eisenstein M. IPSCs: One cell to rule them all? Nat Methods. 2010;7:81-85.
43. Graf T, Enver T. Forcing cells to change lineages. Nature. 2009;462:587-504.
44. Sang Y, Wu M-F, Wagner D. The stem cell-chromatin connection. Semin Cell Dev Biol. 2009;20:1143-1148.
45. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem. 2003;46:5097-5116.
46. Itoh Y, Suzuki T, Kouketsu A, et al. Design, synthesis, structure-selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J Med Chem. 2007;50:5425-5438.
47. Mahboobi S, Sellmer A, Höcher H, et al. 2-Aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors. J Med Chem. 2007;50:4405-4418.
48. Methot JL, Chakravarty PK, Chenard M, et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett. 2008;18:973-978.
49. Kinzel O, Llauger-Bufi L, Pescatore G, et al. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. J Med Chem. 2009;52:3453-3456.
50. Zhang L, Fang H, Xu W. Strategies in developing promising histone deacetylase inhibitors. Med Res Rev. 2010;30:585-602.
51. Pontiki E, Hadjipavlou-Litina D. Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: History and new QSAR perspectives. Med Res Rev. 2012;32:1-165.
52. Addis M, Piredda G, Pirisi A. The use of lamb rennet paste in traditional sheep milk cheese production. Small Ruminant Res. 2008;79:2-10.
53. Santillo A, Albenzio M, Quinto M, et al. Probiotic in lamb rennet paste enhances rennet lipolytic activity, and conjugated linoleic acid and linoleic acid content in pecorino cheese. J Dairy Sci. 2009;92:1330-1337.
54. Miller SJ. Cellular and physiological effects of short-chain fatty acids. Mini Rev Med Chem. 2004;4:839-845.
55. Waldecker M, Kautenburger T, Daumann H, et al. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem. 2008;19:587-593.
56. Scharlau D, Borowicki A, Habermann N, et al. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fiber. Mutat Res. 2009;682:39-53.
57. Serpa J, Caiado F, Carvalho T, et al. Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells. J Biol Chem. 2010;285:39211-39223.
58. Rajendran P, Williams DE, Ho E, et al. Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol. 2011;46:181-199.
59. Terao Y, Nishida J-I, Horiuchi S, et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecological cancer cells. Int J Cancer. 2001;94:257-267.
60. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330-339.
61. Andriamihaja M, Chaumontet C, Tome D, et al. Butyrate metabolism in human colon carcinoma cells: Implications concerning its growth-inhibitory effect. J Cell Physiol. 2009;218:58-65.
62. Zhang Y, Zhou L, Bao YL, et al. Butyrate induces cell apoptosis through activation of JNK MAP kinase pathway in human colon cancer RKO cells. Chem-Biol Interact. 2010; 185:174-181.
63. Crea F, Nobili S, Paolicchi E, et al. Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updates. 2011;14:280-296.
64. Raw1uszko AA, S1awek S, Gollogly A, et al. Effect of butyrate on aromatase cytochrome P450 levels in HT29, DLD-1 and LoVo colon cancer cells. Biomed Pharmacother. 2012; 66:77-82.
65. Rahman R, Grundy R. Histone deacetylase inhibition as an anticancer telomerase-targeting strategy. Int J Cancer. 2011; 129:2765-2774.
66. Liang G, Taranova O, Xia K, et al. Butyrate promotes induced pluripotent stem cell generation. J Biol Chem. 2010; 285:25516-25521.
67. Mali P, Chou B-K, Yen J, et al. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells. 2010;28:713-720.
68. Zhou M, Li P, Tan L, et al. Differentiation of mouse embryonic stem cells into hepatocytes induced by a combination of cytokines and sodium butyrate. J Cell Biochem. 2010; 109:606-614.
69. Lyssiotis CA, Lairson LL, Boitano AE, et al. Chemical control of stem cell fate and developmental potential. Angew Chem Int Ed. 2011;50:200-242.
70. Ariff IM, Mitra A, Anirban Basu A. Epigenetic regulation of self-renewal and fate determination in neural stem cells. J Neurosci Res. 2012;90:529-539.
71. Mali P, Cheng L. Concise review: Human cell engineering: Cellular reprogramming and genome editing. Stem Cells. 2012;30:75-81.
72. Roy M-J, Dionne S, Marx G, et al. In vitro studies on the inhibition of colon cancer by butyrate and carnitine. Nutrition. 2009;25:1193-1201.
73. Blouin J-M, Penot G, Collinet M, et al. Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. Int J Cancer. 2011;128: 2591-2601.
74. Canani RB, Di Costanzo M, Leone L. The epigenetic effects of butyrate: Potential therapeutic implications for clinical practice. Clin Epigenetics. 2012;4:4.
75. Guan J-S, Haggarty SJ, Giacometti E, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009, 459:55-60.
76. Kim HJ, Leeds P, Chuang D-M. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem. 2009;110:1226-1240.
77. Best JD, Carey N. Epigenetic therapies for non-oncology indications. Drug Discov Today. 2010;15:1008-1014.
78. McGee-Lawrence ME, Westendorf JJ. Histone deacetylases in skeletal development and bone mass maintenance. Gene. 2011;474:1-11.
79. Sampathkumar S-G, Jones MB, Meledeo MA, et al. Targeting glycosylation pathways and the cell cycle: Sugardependent activity of butyrate-carbohydrate cancer prodrugs. Chem Biol. 2006;13:1265-1275.
80. Pajak B, Orzechowski A, Gajkowska B. Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells. Adv Med Sci. 2007;52:83-88.
81. Lee S, Park J-R, Seo M-S, et al. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif. 2009;42:711-722.
82. Gao Z, Yin J, Zhang J, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009;58:1509-1517.
83. Pace BS, White GL, Dover GJ, et al. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood. 2002;100:4640-4648.
84. Perrine SP. Fetal globin induction-can it cure b thalassemia? Hematology. 2005;1:38-44.
85. Perrine SP, Mankidy R, Boosalis MS, et al. Erythroid Kruppel-like factor (EKLF) is recruited to the c-globin gene promoter as a co-activator and is required for c-globin gene induction by short-chain fatty acid derivatives. Eur J Haematol. 2009;82:466-476.
86. Canani RB, Di Costanzo M, Leone L, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17:1519-1528.
87. Machado-Vieira R, Ibrahim L, Zarate, Jr., CA. Histone deacetylases and mood disorders: Epigenetic programming in gene-environment interactions. CNS Neurosci Ther. 2011;17:699-704.
88. Wang A, Si H, Liu D, et al. Butyrate activates the cAMPprotein kinase A cAMP response element-binding protein signaling pathway in Caco-2 cells. J Nutr. 2012;142:1-6.
89. Witt O, Mönkemeyer S, Rönndahl G, et al. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood. 2003;101:2001-2007.
90. Entin-Meer M, Rephaeli A, Yang X, et al. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Cancer Ther. 2005;4:1952-1961.
91. Bohacek R, Boosalis MS, McMartin C, et al. Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models. Chem Biol Drug Des. 2006;67:318-328.
92. Riester D, Hildmann C, Schwienhorst A. Histone deacetylase inhibitors-turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Appl Microbiol Biotechnol. 2007;75: 499-514.
93. Parise RA, Beumera JH, Kangani CO, et al. Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. J Chromatogr B. 2008;862:168-174.
94. Kuroiwa-Trzmielina J, de Conti A, Scolastici C, et al. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: Efficacy of tributyrin, a butyric acid prodrug. Int J Cancer. 2009;124:2520-2527.
95. Ghosh SK, Perrine SP, Williams RM, et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood. 2012;119:1008-1017.
96. Nudelman A, Gnizi E, Katz Y, et al. Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur J Med. 2001;36:63-74.
97. Kessler-Icekson G, Hochhauser E, Sinai T, et al. A histone deacetylase inhibitory prodrug-butyroyloxymethyl diethyl phosphate-protects the heart and cardiomyocytes against ischemia injury. Eur J Pharm Sci. 2012;45:592-599.
98. Rephaeli A, Entin-Meer M, Angel D, et al. The selectivity and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Invest New Drugs. 2006;24:383-392.
99. Chung MC, Ferreira EI, Santos JL, et al. Prodrugs for the treatment of neglected diseases. Molecules. 2008;13:616-677.
100. Tarasenko N, Nudelman A, Tarasenko I, et al. Histone deacetylase inhibitors: The anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin Exp Metastasis. 2008;25:703-716.
101. Mai A, Altucci L. Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol. 2009;41:199-213.
102. Perrine SP, Ginder G, Faller DV, et al. A short-term trial of butyrate to stimulate fetal globin gene expression in the b globin gene disorders. N Engl J Med. 1993;328:81-86.
103. Atweh GF, Dover GJ, Ikuta T, et al. Hematologic responses to pulse butyrate therapy in the beta-hemoglobinopathies. Blood. 1999;93:1790-1797.
104. Perrine SP, Castaneda SA, Chui DH, et al. Fetal globin gene inducers: Novel agents and new potential. Ann NY Acad Sci. 2010;1202:158-164.
105. McMahon L, Tamary H, Askin M, et al. A randomized phase II trial of arginine butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol. 2010;151:516-524.
106. Bora-Tatar G, Dayangaç-Erden D, Demir AS, et al. Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies. Bioorg Med Chem. 2009;17:5219-5228.
107. Li G-F, Qian T-L, Li G-S, et al. Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. Genet Mol Res. 2012;11:77-86.
108. Gilbert KM, DeLoose A, Valentine JL, et al. Structure- activity relationship between carboxylic acids and T cell cycle blockade. Life Sci. 2006;78:2159-2165.
109. Boosalis MS, Bandyopadhyay R, Bresnick EH, et al. Shortchain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood. 2001;97:3259-3267.
110. Castaneda S, Boosalis MS, Emery D, et al. Enhancement of growth and survival and alterations in Bcl-family proteins in β-thalassemic erythroid progenitors by novel shortchain fatty acid derivatives. Blood Cells Mol Dis. 2005;35: 217-226.
111. 2+ -chelating motiftethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004;47:467-474.
112. Lu Q, Wang D-S, Chen C-S, et al. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005;48:5530-5535.
113. Bieliauskas AV, Weerasinghe SVW, Pflum MKH. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bioorg Med Chem Lett. 2007;17:2216-2219.
114. Witter DJ, Harrington P, Wilson KJ, et al. Optimization of biaryl selective HDAC1&2 inhibitors (SHI-1:2). Bioorg Med Chem Lett. 2008;18:726-731.
115. Andrianov V, Gailite V, Lola D, et al. Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR. Eur J Med Chem. 2009;44:1067-1085.
116. Martinet N, Bertrand P. Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manage Res. 2011;3: 117-141.
117. Thangaraju M, Carswell KN, Prasad PD, et al. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J. 2009; 417:379-389.
118. Steliou K, Perrine SP, Faller DV. Lactic acid in cancer and mitochondrial disease. Drug Dev Res. 2009;70:499-511.
119. Gupta N, Martin PM, Prasad PD, et al. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci. 2006; 78:2419-2425.
120. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond. Pharmacol Therapeut. 2009;121:29-40.
121. Brown AJ, Jupe S, Briscoe CP. A family of fatty acid binding receptors. DNA Cell Biol. 2005;24:54-61.
122. Aich U, Yarema KJ. Non-natural sugar analogues: Chemical probes for metabolic oligosaccharide engineering. In: Glycoscience. Fraser-Reid B, Tatsuta K, Thiem J. (eds.) Springer-Verlag: Berlin, Germany; pp. 2133-2190; 2008.
123. Zhang H, Ma Y, Sun X-L. Recent developments in carbohydrate-decorated targeted drug/gene delivery. Med Res Rev. 2010;30:270-289.
124. Mertens K, Mees G, Lambert B, et al. In vitro 2-deoxy-2-[18F]fluoro-D-glucose uptake: Practical considerations. Cancer Biother Radiopharm. 2012;27:183-188.
125. Elmouelhi N, Aich U, Paruchuri VDP, et al. Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery. J Med Chem. 2009;52: 2515-2530.
126. Stallforth P, Lepenies B, Adibekian A, et al. Carbohydrates: A frontier in medicinal chemistry. J Med Chem. 2009;52: 5561-5577.
127. Wang Z, Du J, Che P-L, et al. Hexosamine analogs: From metabolic glycoengineering to drug discovery. Curr Opin Chem Biol. 2009;13:565-572.
128. Kim EJ, Jones MB, Rhee JK, et al. Establishment of N-acetylmannosamine (ManNAc) analogue-resistant cell lines as improved hosts for sialic acid engineering applications. Biotechnol Prog. 2004;20:1674-1682.
129. Campbell CT, Sampathkumar S-G, Yarema KJ. Metabolic oligosaccharide engineering: Perspectives, applications, and future directions. Mol Biosyst. 2007;3:187-194.
130. Campbell CT, Aich U, Weier CA, et al. Targeting proinvasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells. J Med Chem. 2008;51:8135-8147.
131. Almaraz RT, Aich U, Khanna HS, et al. Metabolic oligosaccharide engineering with N-acyl functionalized ManNAc analogs: Cytotoxicity, metabolic flux, and glycan-display considerations. Biotechnol Bioeng. 2012;109:992-1006.
132. Parameshwaran K, Irwin MH, Steliou K, et al. D-Galactose effectiveness in modeling aging and therapeutic antioxidant treatment in mice. Rejuv Res. 2010;13:729-735.
133. Parameshwaran K, Irwin MH, Steliou K, et al. Antioxidant protection of rotenone-induced neuromotor decline, ROS generation and cellular stress in mouse brain. Pharmacol Biochem Behav. 2012;101:487-492.
134. Na1ezcz KA, Miecz D, Berezowski V, et al. Carnitine: Transport and physiological functions in the brain. Mol Aspects Med. 2004;25:551-567.
135. 0,+. Am J Physiol Gastrointest Liver Physiol. 2007;293: G1046-G1053.
136. Gong X-w, Li J-p, Wu J-f, et al. Synthesis of carnitine benzyl esters as prodrugs. J Chem Res. 2008;2008:327-330.
137. Piermatti O, Fringuelli F, Pochini L, et al. Synthesis and characterization of carnitine nitro-derivatives. Bioorg Med Chem. 2008;16:1444-1451.
138. Rosca MG, Lemieux H, Hoppel CL. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? Adv Drug Deliver Rev. 2009;61:1332-1342.
139. Knoop F. Der abbau aromatischer fettsäuren im tierkörper (The degradation of aromatic fatty acids in the animal body). Beitr Chem Physiol Pathol. 1904;6:150-162.
140. Houten SM, Wanders RJA. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis. 2010;33:469-477.
141. Bieber LL. Carnitine. Annu Rev Biochem. 1988;57:261-283.
142. Bieber LL, Emaus R, Valkner K, et al. Possible functions of short-chain and medium-chain carnitine acyltransferases. Fed Proc. 1982;41:2858-2862.